Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655118 · ClinicalTrials.gov registry record · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
A Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis, sponsored by Telios Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 20
- Study locations
NCT04655118: Recruiting Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis, sponsored by Telios Pharma.
NCT04655118 is a Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis that is actively recruiting participants, run by Telios Pharma. The registered enrollment target is 121 participants, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04655118, a Phase 2 study of Myelofibrosis and Indolent Systemic Mastocytosis, is actively recruiting participants, sponsored by Telios Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TL-895
Study Locations (20)
Other
- Border Medical Oncology - East Albury
- Southern Oncology Specialists - Kogarah
- Royal Perth Hospital - Perth
- St Vincent's Hospital Sydney - Sydney
- Chu De Liège - Liège
- Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Instituto de Estudos e Pesquisas Sao Lucas - IEP - Sao Lucas - São Paulo
- University Hospital "St Ivan Rilski" - Sofia
- Military Medical Academy - Sofia
- CH Le Mans - Le Mans
- CHU de Nantes - Hôtel-Dieu - Nantes
- CHU de Nice - Hopital L' Archet II - Nice
- Universitaetsklinikum Carl Gustav Carus Dresden - Dresden
- Marien Hospital Duesseldorf - Düsseldorf
Ohio
- Gabrail Cancer Center - Canton
- University of Cincinnati (UC) Physicians Company, LLC - Cincinnati
- Ohio State University - Columbus
Colorado
- University of Colorado - Aurora Cancer Center - Aurora
Minnesota
- Mayo Clinic - Rochester - Rochester
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-10-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What NCT04655118 shows while recruiting
NCT04655118 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04655118 names 20 study sites across 5 states, led by Other, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT04655118 about?
NCT04655118 is a clinical study titled "Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis". This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., havin...
What is the current status of trial NCT04655118?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2020-10-22. Estimated completion is 2025-12-31.
What conditions does trial NCT04655118 study?
This clinical trial studies the following conditions: Myelofibrosis, Indolent Systemic Mastocytosis.
What interventions are being tested in trial NCT04655118?
The interventions under investigation include: Placebo (DRUG), TL-895 (DRUG).
Who is sponsoring clinical trial NCT04655118?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04655118 being conducted?
This trial has 20 study locations across Colorado, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04655118's enrollment target sits among peer trials
121 20th of 61 higher than 42 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT05488431 · 121 participants · Phase 2
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI